Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Cancer, Cancer (Colon Cancer, Breast Can...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to establish a safe and systematic exercise assessment and prescription program for cancer survivors. It can be challenging for cancer patients to start exercising due to various health risks, so this study aims to create a personalized and easily reproducible workflow. The study will include cancer patients who have completed their primary curative treatments at least 2 months ago. Participants will undergo a comprehensive health and fitness evaluation led by a study physician. This evaluation includes: * A review of medical history and cardiovascular risk. * Functional physical fitness tests. * Cardiopulmonary Exercise Testing (CPET) to carefully evaluate heart and lung function during physical exertion. * A musculoskeletal ultrasound, if deemed necessary. Based on these combined results, the medical team will determine each participant's exercise risk level and design a personalized exercise prescription. Participants will then be assigned to an appropriate and safe exercise setting. To ensure safety and maximize health benefits, the study includes a continuous tracking system. Participants will report their exercise progress every 4 weeks and undergo a full reassessment every 3 months. The medical team will use this feedback to safely adjust the participant's risk level and exercise prescription over time.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: structured exercise training — This study utilizes a "Personalized Precision Exercise Training Program." Following baseline Cardiopulmonary Exercise Testing (CPET) and comprehensive fitness assessments, physicians prescribe individualized regimens adhering to ACSM guidelines for cancer survivors, applying the FITT principle: * Aerobic Exercise: 3-5 days/week at moderate intensity, tailored to treatment tolerance. ≥30 mins/session, flexibly adjusted for treatment side effects. Focuses on rhythmic activities (walking, cycling). * Resistance Training: 2-3 days/week (48h rest per muscle group) at 60-80% 1-RM or a load for 6-15 reps. Employs progressive overload without requiring muscular failure. Involves 8-10 major muscle groups; ≥1 set/exercise, ≥6 reps/set, with ≥60s rest between sets. Modalities adapt to patient status. * Flexibility Training: ≥2-3 days/week (up to daily). Static stretches (10-30s hold, 2-4 reps, stretching to mild discomfort but avoiding pain) covering all major muscles.

Primary Outcomes

  • Dominant Handgrip Strength Test (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
  • 30-Second Arm Curl Test (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
  • 30-Second Chair Stand Test (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
  • Single-Leg Stance Test (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
  • 6-Minute Walk Distance (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
  • Peak Oxygen Consumption (Peak VO2) (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
  • Peak Work Rate (Pre-intervention (T0), after 3 months of intervention (T1), and 6 months after intervention (T2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-12
Completion: 2027-08-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Contact Information
Study Contact:
Ko-Long Lin, PhD
886-978-862-831
klin967@gmail.com
Ko-Long Lin, PhD
886-978-862-831
klin967@gmail.com
Kaohsiung Medical University Chung-Ho Memorial Hospital
Interventions
  • Other: structured exercise training — This study utilizes a "Personalized Precision Exercise Training Program." Following baseline Cardiopulmonary Exercise Testing (CPET) and comprehensive fitness assessments, physicians prescribe individualized regimens adhering to ACSM guidelines for cancer survivors, applying the FITT principle: * Aerobic Exercise: 3-5 days/week at moderate intensity, tailored to treatment tolerance. ≥30 mins/session, flexibly adjusted for treatment side effects. Focuses on rhythmic activities (walking, cycling). * Resistance Training: 2-3 days/week (48h rest per muscle group) at 60-80% 1-RM or a load for 6-15 reps. Employs progressive overload without requiring muscular failure. Involves 8-10 major muscle groups; ≥1 set/exercise, ≥6 reps/set, with ≥60s rest between sets. Modalities adapt to patient status. * Flexibility Training: ≥2-3 days/week (up to daily). Static stretches (10-30s hold, 2-4 reps, stretching to mild discomfort but avoiding pain) covering all major muscles.
Study Locations (1 sites)
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan 807 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 to 80 years. 2. Cancer Cohorts: Pathologically confirmed diagnosis of AJCC TNM stage I-III, and having completed curative-intent treatment (including surgery ± adjuvant chemotherapy/radiotherapy, etc) for at least 2 months. 3. Cancer cohort must have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2. 4. Ability to comply with weekly structured exercise training (3-4 professionally supervised sessions per week) and willingness to accept telephone follow-ups or report exercise status via exercise logs/wearable devices. 5. Self-reported failure to meet the following physical activity guidelines within the past 3 months: at least 150 minutes of moderate-intensity aerobic exercise per week OR at least 75 minutes of vigorous-intensity aerobic exercise per week; AND no regular resistance training (≥ 2 sessions per week) within the past 3 months. Exclusion Criteria: 1. Cardiovascular instability: History of acute coronary syndrome (ACS), myocardial infarction (MI), acute exacerbation of heart failure, or hospitalization for heart failure within the past 3 months; unstable angina; uncontrolled arrhythmia; or uncontrolled hypertension (resting blood pressure \> 180/110 mmHg). 2. Hypoxemia: Resting oxygen saturation (SpO2) \< 90%. 3. Metabolic instability: Severe hypoglycemic event or diabetic ketoacidosis (DKA) within the past 3 months. 4. Musculoskeletal or neurological risks: Unstable bone metastasis or bone metastasis with a high risk of fracture; recent major fracture or orthopedic surgery where weight-bearing is not yet permitted; or other severe neuromuscular diseases that compromise the safety of exercise. 5. Hematological risks: Thrombocytopenia (Platelet count \< 50,000/μL), severe anemia (Hemoglobin \[Hb\] \< 8 g/dL), or neutropenia (Absolute Neutrophil Count \[ANC\] \< 1,000/μL). 6. Deemed unsuitable for exercise intervention as determined by clinical assessment from the attending physician or study investigator. 7. Concurrent participation in other formal exercise or weight-loss intervention programs. 8. Inability to comprehend or complete the informed consent form, or inability to comply with the study procedures.
Conditions Breast Cancer
Phase NA
Enrollment 270
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The scientific goals of the project are: 1. The primary scientific objective of the study is to determine the effectiveness of an eHealth self-management support program for persistent pain after breast cancer treatment compared to: * usual care (i.e. superiority of the eHealth self-management support program) and * a comprehensive pain rehabilitation program delivered face-to-face in a physical therapy setting (i.e. non-inferiority of the eHealth self-management support program) on pain-related disability (measured with the Pain Disability Index). 2. The secondary scientific objectives of this study entails to examine if the eHealth self-management support program has a relative benefit for other biopsychosocial factors, including: * Other dimensions of pain * Health-related quality of life * Physical functioning, including physical activity levels * Psychosocial functioning, including self-efficacy, stress, anxiety, depression, coping style (key secondary outcome) and fear of cancer recurrence * Participation in society, including return to work * Healthcare-related costs for the patient and society 3. The tertiary scientific objectives of this study are * to identify moderators of treatment effect, including behavioural determinants (e.g. self-efficacy, motivation, coping style), in order to identify breast cancer survivors who would benefit the most of the eHealth self-management support program and to allow more stratified and efficient pain management care and more targeted allocation of budgets. * To examine the implementation process, mechanisms of impact and contextual factors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: eHealth self-management support program — This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.
  • Behavioral: Face-to-face rehabilitation program — The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.

Primary Outcomes

  • Pain-related disability (at 6 months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-26
Completion: 2029-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 270 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiteit Antwerpen
Collaborators: Universitaire Ziekenhuizen KU Leuven, University Ghent, KU Leuven, University Hospital, Antwerp
Principal Investigators:
  • An De Groef, PhD (PRINCIPAL_INVESTIGATOR) - Universiteit Antwerpen
  • Nele Devoogdt, PhD (PRINCIPAL_INVESTIGATOR) - KU Leuven
  • Geert Crombez, PhD (PRINCIPAL_INVESTIGATOR) - UGent
Contact Information
Study Contact:
An De Groef, PhD
003216342171
an.degroef@uantwerpen.be
Lore Dams, PhD
lore.dams@uantwerpen.be
An De Groef, PhD
an.degroef@uantwerpen.be
Universiteit Antwerpen
Interventions
  • Behavioral: eHealth self-management support program — This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.
  • Behavioral: Face-to-face rehabilitation program — The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
Study Locations (2 sites)
Universiteit Antwerpen, Antwerp, Belgium
KU Leuven, Leuven, Belgium
Eligibility Criteria
Inclusion criteria * Patients (men and women) with primary breast cancer and with unilateral or bilateral axillary surgery (Axillary Lymph Node Dissection or Sentinel Node Biopsy); * Be non-metastatic and have finished their primary treatment with a curative intent at least 3 months prior to study participation; * Adjuvant hormonal therapy and immunotherapy form the exception to the rule are tolerated; * Presence of self-reported persistent pain in the last 3 months that interferes with daily activities (yes/no) Exclusion criteria * Can not participate during the entire study period; * Mentally or physically unable to participate in the study; * Previous participation in a pain science education program. * No acces to a digital device * Do not speak/understand Dutch
Conditions Acute Pain, Post Operative Analgesia, Po...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Postoperative pain management is crucial for patients undergoing mastectomy for breast cancer. Regional analgesia techniques, such as the Thoracic Paravertebral Block (TPVB), are commonly used to reduce pain and opioid consumption; however, TPVB carries potential risks, including pneumothorax. Interfascial plane blocks, specifically the Pectoral Nerve II (PECS II) block combined with the Superficial Parasternal Intercostal Plane (PIP) block, have emerged as alternative techniques to provide comprehensive analgesia to both the lateral and anterior chest wall. The purpose of this randomized controlled trial is to evaluate and compare the analgesic efficacy and quality of postoperative recovery between a combination of ultrasound-guided PECS II and PIP blocks versus the standard Thoracic Paravertebral Block (TPVB) in patients undergoing mastectomy with or without axillary lymph node dissection (ALND). Participants will be randomly assigned to receive either the combined PECS II and PIP block or the TPVB following general anesthesia induction. Pain scores, total opioid consumption, time to first analgesic request, quality of recovery using the QoR-15 questionnaire, and potential block-related complications will be monitored and compared over the 24-hour postoperative period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Procedure: Combined PECS II and Superficial PIP Block — Ultrasound-guided regional nerve block administration consisting of PECS II block (25 mL 0.25% Bupivacaine) and superficial PIP block (10 mL 0.25% Bupivacaine) post-induction of general anesthesia prior to surgical incision.
  • Procedure: Thoracic paravertebral block (TPVB) — Ultrasound-guided regional nerve block administration consisting of TPVB with 0.25% Bupivacaine (5 mL at T4 level and 5 mL at T6 level) post-induction of general anesthesia prior to surgical incision.

Primary Outcomes

  • Postoperative Quality of Recovery Score (QoR-15) (24 hours postoperatively)
  • Postoperative Pain Severity (NRS) (Postoperative hours 0, 6, 12, and 24)
  • Duration of Analgesia (Up to 24 hours postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-29
Completion: 2026-12-31
Eligibility
Age: 18 Years – 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dharmais National Cancer Center Hospital
Contact Information
Study Contact:
Annisa Annisa, Anesthesiologist
81317235246
annisa157sasa@gmail.com
Annisa Annisa, Anesthesiologist
81317235246
annisa157sasa@gmail.com
Dharmais National Cancer Center Hospital
Interventions
  • Procedure: Combined PECS II and Superficial PIP Block — Ultrasound-guided regional nerve block administration consisting of PECS II block (25 mL 0.25% Bupivacaine) and superficial PIP block (10 mL 0.25% Bupivacaine) post-induction of general anesthesia prior to surgical incision.
  • Procedure: Thoracic paravertebral block (TPVB) — Ultrasound-guided regional nerve block administration consisting of TPVB with 0.25% Bupivacaine (5 mL at T4 level and 5 mL at T6 level) post-induction of general anesthesia prior to surgical incision.
Study Locations (1 sites)
Dharmais National Cancer Center Hospital, Jakarta, DKI Jakarta 11420 Indonesia
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18 to 60 years. 2. Scheduled for breast cancer surgery (mastectomy with or without axillary lymph node dissection \[ALND\]). 3. American Society of Anesthesiologists (ASA) physical status I to III. 4. Provided signed written informed consent to participate in the study. Exclusion Criteria: 1. Patient refusal to participate in the study. 2. Known allergy to local anesthetics or study medications (e.g., bupivacaine, ketorolac, morphine). 3. Coagulation disorders or coagulopathy. 4. Mastectomy procedure with immediate breast reconstruction. 5. Pre-existing chronic cancer pain with active usage of strong opioids (e.g., morphine, fentanyl). 6. Cognitive impairment or inability to comprehend the pain assessment scale (NRS). 7. Pregnancy. 8. Active infection at the planned regional block injection site.
Conditions Breast Cancer
Phase PHASE3
Enrollment 502
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The DIAMOND study (DIAMOND-01) is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial conducted by Fudan University Shanghai Cancer Center. The study aims to evaluate the efficacy and safety of an oral, "non-intravenous" regimen (pyrotinib + trastuzumab \[subcutaneous\] + dalpiciclib) compared to a standard intravenous chemotherapy-containing regimen (pyrotinib + trastuzumab \[subcutaneous\] + docetaxel) in patients with advanced HER2-positive breast cancer. Approximately 502 patients with histologically confirmed advanced HER2-positive breast cancer who have received at most one prior line of systemic therapy (including anti-HER2 treatment) in the advanced setting will be randomized 1:1 to either the experimental or control arm. Stratification factors include ER status and presence of visceral metastases. The primary endpoint is Progression-Free Survival (PFS). Key secondary endpoints include Overall Survival (OS), Objective Response Rate (ORR), Disease Control Rate (DCR), Clinical Benefit Rate (CBR), safety, and patient-reported quality of life. Exploratory endpoints involve correlating circulating tumor cells (CTCs) and PAM50 molecular subtyping with survival outcomes. This study seeks to determine if the all-oral, chemotherapy-free combination is non-inferior to the standard chemo-containing regimen, potentially offering a less toxic and more convenient treatment option for patients with advanced HER2-positive breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w — Pyrotinib: 320 mg, administered orally once daily. It should be taken within 30 minutes after breakfast. Dosing continues until disease progression or unacceptable toxicity occurs as defined by the protocol. If a dose is missed, underdosed, or vomiting occurs after ingestion, the missed dose should not be made up. The event should be recorded, and the next dose should be taken as scheduled. Dalpiciclib: 125 mg, administered orally once daily at approximately the same time each day. Patients must fast for at least 1 hour before and after administration. It is taken continuously for 21 days, followed by a 7-day break, comprising one 28-day treatment cycle. Trastuzumab: A fixed dose of 600 mg (not weight-based) administered subcutaneously every three weeks. Each injection should be completed over 2-5 minutes. Endocrine Therapy: For HR-positive patients, the decision to administer endocrine therapy in the experimental group will be at the investigator's discretion after 6 cycles
  • Drug: Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Docetaxel 75mg/m² ivgtt d1 q3w, — Pyrotinib: 400 mg, administered orally once daily. It should be taken within 30 minutes after breakfast. Dosing continues until disease progression or unacceptable toxicity occurs as defined by the protocol. If a dose is missed, underdosed, or vomiting occurs after ingestion, the missed dose should not be made up. The event should be recorded, and the next dose should be taken as scheduled. Trastuzumab: A fixed dose of 600 mg (not weight-based) administered subcutaneously every three weeks. Each injection should be completed over 2-5 minutes. Docetaxel: 75 mg/m², administered by intravenous infusion every 21 days as one cycle, for a total of 6 cycles.For HR-positive patients, whether to administer endocrine therapy in the experimental group after 6 cycles of docetaxel may be determined at the investigator's discretion. However, the use of CDK4/6 inhibitors is prohibited.

Primary Outcomes

  • PFS (from initial treatment until disease progression, death, loss to follow-up, or study completion,up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-02-12
Completion: 2029-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 502 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Hongxia Wang, Chief physician (PRINCIPAL_INVESTIGATOR) - Fudan University Principal Investigator Biyun Wang , Chief physician Fudan University
Contact Information
Study Contact:
Hongxia Wang Chief physician
86-138196379
whx365@126.com
Ting Li Associate chief physician
+86-18121299346
cinderellaliting@126.com
Hongxia Wang
+8621-38196379
whx365@126.com
Fudan Cancer Hospital
Interventions
  • Drug: Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w — Pyrotinib: 320 mg, administered orally once daily. It should be taken within 30 minutes after breakfast. Dosing continues until disease progression or unacceptable toxicity occurs as defined by the protocol. If a dose is missed, underdosed, or vomiting occurs after ingestion, the missed dose should not be made up. The event should be recorded, and the next dose should be taken as scheduled. Dalpiciclib: 125 mg, administered orally once daily at approximately the same time each day. Patients must fast for at least 1 hour before and after administration. It is taken continuously for 21 days, followed by a 7-day break, comprising one 28-day treatment cycle. Trastuzumab: A fixed dose of 600 mg (not weight-based) administered subcutaneously every three weeks. Each injection should be completed over 2-5 minutes. Endocrine Therapy: For HR-positive patients, the decision to administer endocrine therapy in the experimental group will be at the investigator's discretion after 6 cycles
  • Drug: Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Docetaxel 75mg/m² ivgtt d1 q3w, — Pyrotinib: 400 mg, administered orally once daily. It should be taken within 30 minutes after breakfast. Dosing continues until disease progression or unacceptable toxicity occurs as defined by the protocol. If a dose is missed, underdosed, or vomiting occurs after ingestion, the missed dose should not be made up. The event should be recorded, and the next dose should be taken as scheduled. Trastuzumab: A fixed dose of 600 mg (not weight-based) administered subcutaneously every three weeks. Each injection should be completed over 2-5 minutes. Docetaxel: 75 mg/m², administered by intravenous infusion every 21 days as one cycle, for a total of 6 cycles.For HR-positive patients, whether to administer endocrine therapy in the experimental group after 6 cycles of docetaxel may be determined at the investigator's discretion. However, the use of CDK4/6 inhibitors is prohibited.
Study Locations (1 sites)
Fudan Cancer Hospital, Shanghai, Shanghai Municipality 200230 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients with histopathologically confirmed recurrent/metastatic breast cancer that is HER2-positive (HER2 positivity is defined as IHC 3+, or IHC 2+/FISH amplified), based on the most recent pathological report. 3. Hormone receptor status is known, based on the most recent pathological report. 4. At least one measurable lesion meeting RECIST 1.1 criteria. 5. Have received no more than one prior line of systemic anti-tumor therapy for the advanced stage, which may include anti-HER2 therapy, chemotherapy, targeted therapy, immunotherapy, etc. 6. ECOG performance status of 0 to 1. 7. Adequate organ function meeting the following requirements: * Blood Routine: ANC ≥ 1.5 × 10⁹/L; PLT ≥ 75 × 10⁹/L; Hb ≥ 90 g/L (transfusion or medication to maintain hemoglobin level is permitted). * Blood Biochemistry: TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN (≤ 5.0 × ULN in patients with liver metastases); BUN or Cr ≤ 1.5 × ULN OR Creatinine Clearance ≥ 50 mL/min (calculated by Cockcroft-Gault formula). * 12-Lead ECG: QTcF \< 470 ms for females, \< 450 ms for males. * Cardiac Ultrasound: LVEF ≥ 50%. 8. Prior use of TKI drugs (including but not limited to pyrotinib or neratinib) in the neoadjuvant/adjuvant setting is permitted, provided the following conditions are both met: * The patient did not experience disease progression or recurrence/metastasis during the prior TKI therapy. * There was a period of ≥ 6 months between the discontinuation of the prior TKI and the occurrence of disease progression or recurrence/metastasis. 9. Recovery from any adverse events related to prior anti-tumor therapies to Grade ≤1 (according to NCI-CTCAE v5.0) before the first dose of study drug, with the exception of: a. Alopecia; b. Pigmentation. 10. The subject voluntarily participates in the study, has signed the Informed Consent Form (ICF), demonstrates good compliance, and is willing to cooperate with follow-up Exclusion Criteria: 1. Presence of symptomatic brain metastases or leptomeningeal metastases. 2. Active brain metastases, except for asymptomatic brain metastases or those that have been stable for at least 4 weeks after local treatment. 3. Inability to swallow, presence of intestinal obstruction, or other factors affecting drug administration and absorption. 4. Presence of uncontrolled third-space fluid accumulation (e.g., massive pleural effusion or ascites) that cannot be managed by drainage or other methods. 5. Received radiotherapy, chemotherapy, or targeted therapy within 4 weeks prior to enrollment, or endocrine therapy within 2 weeks prior to enrollment. (Bisphosphonates used for treating bone metastases or preventing osteoporosis are excluded from this restriction). Or, current participation in any interventional drug clinical trial. 6. Pregnant or lactating female subjects, or subjects of childbearing potential with a positive baseline pregnancy test, or unwilling to use effective contraception. 7. History of other active malignancies within the past 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and cutaneous squamous cell carcinoma). 8. Major surgical procedure or significant trauma within 4 weeks prior to randomization, or anticipation of the need for major surgery during the study. 9. Known history of allergy to any component of the study drug regimen. 10. Subjects with cardiac insufficiency, including but not limited to: congestive heart failure, transmural myocardial infarction, angina pectoris requiring medication, clinically significant valvular heart disease, and high-risk arrhythmias. 11. Active hepatitis (For hepatitis B: HBsAg positive AND HBV DNA ≥ 1000 IU/mL; For hepatitis C: HCV antibody positive AND HCV RNA above the upper limit of normal). 12. Uncontrolled hypertension (resting blood pressure: systolic \> 160 mmHg or diastolic \> 100 mmHg). 13. History of definite neurological or psychiatric disorders, including epilepsy or dementia. 14. Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in this study. This includes any concomitant illness or condition that could interfere with study participation, or any serious medical disorder that might affect subject safety (e.g., active or uncontrolled infection, severe diabetes, immunodeficiency disease, etc.).
Conditions Anatomic Stage III Breast Cancer AJCC v8...
Phase PHASE1
Enrollment 57
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Immunotherapy with monoclonal antibodies, such as pembrolizumab may help the body's immune system attach the cancer and may interfere with the ability of tumor cells to grow and spread. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Combination therapy with ZEN003694 pembrolizumab immunotherapy and nab-paclitaxel chemotherapy may help shrink or stabilize cancer for longer than chemotherapy alone.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BET Bromodomain Inhibitor ZEN-3694 — Given PO
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Computed Tomography — Undergo CT
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Drug: Nab-paclitaxel — Given IV
  • Biological: Pembrolizumab — Given IV

Primary Outcomes

  • Maximum tolerated dose (MTD) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxel (Up to 28 days from start of treatment)
  • Recommended phase 2 dose (RP2D) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxel (Up to 28 days from start of treatment)
  • Incidence of adverse events (Up to 3 years from treatment start date)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-05-18
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 57 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Ana C Garrido-Castro (PRINCIPAL_INVESTIGATOR) - Dana-Farber - Harvard Cancer Center LAO
Contact Information
Study Contact:
Site Public Contact
877-442-3324
Dana-Farber Cancer Institute
Ana C. Garrido-Castro
Dana-Farber Cancer Institute
Site Public Contact
212-263-4432
cancertrials@nyulangone.org
NYU Langone Hospital - Long Island
Interventions
  • Drug: BET Bromodomain Inhibitor ZEN-3694 — Given PO
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Computed Tomography — Undergo CT
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
Study Locations (6 sites)
Boston Medical Center, Boston, Massachusetts 02118 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
NYU Langone Hospital - Long Island, Mineola, New York 11501 United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York 10016 United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee 37204 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have a histologically or cytologically confirmed diagnosis of TNBC based on standard criteria for the disease: * Estrogen receptor (ER) and progesterone receptor (PR) \< 10% by immunohistochemistry (IHC), and HER2-negative (per current American Society of Clinical Oncology \[ASCO\]/College of American Pathologists \[CAP\] guidelines) * If there is more than one histological result available, the most recent sample with ER, PR and HER2 results will be considered for inclusion * Patients who have not had ER, PR and HER2 testing and thus, ER, PR and HER2 status is unknown, are not eligible * Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation * Participants must have disease that is unresectable locally advanced or metastatic * DOSE ESCALATION COHORT: Known PD-L1 status is not required prior to study enrollment. Central PD-L1 testing (on archival tumor tissue) will occur retrospectively * DOSE ESCALATION COHORT: Any number of prior lines of therapy are allowed in the metastatic setting. Prior immune checkpoint inhibitor allowed in any setting * DOSE ESCALATION COHORT: Evaluable or measurable disease per RECIST 1.1 criteria * DOSE EXPANSION COHORT: PD-L1 status must be negative. Standard local testing with any PD-L1 antibody that has been validated in a Clinical Laboratory Improvement Act (CLIA)- certified environment will be acceptable for including patients on trial. Primary or metastatic samples may be tested for PD-L1 status. Central confirmation will occur retrospectively. For patients in whom a baseline research tumor tissue biopsy is not performed (e.g. site of disease is not safely accessible), archival tissue should be provided for central confirmatory PD-L1 testing * DOSE EXPANSION COHORT: 0-1 prior lines of systemic therapy in the metastatic setting * DOSE EXPANSION COHORT: Participants must have measurable disease per RECIST 1.1 criteria * DOSE EXPANSION COHORT: Participants must have disease that is amenable to biopsy as judged by the treating investigator and must be willing to undergo pre- and on-treatment tumor biopsies, if safely accessible * Age \>= 18 years * Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with nab-paclitaxel and pembrolizumab (MK-3475) in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Absolute neutrophil count \>= 1,000/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 9 g/dL or \>= 5.6 mmol/L * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (or =\< 2.0 x ULN in patients with documented Gilbert's Syndrome) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 3.0 x institutional ULN or ≤ 5.0 x institutional ULN for participants with documented liver metastases * Serum or plasma creatinine =\< 1.5 x institutional ULN OR glomerular filtration rate (GFR) \>= 60 mL/min (based on the calculated chronic kidney disease epidemiology (CKD-EPI) glomerular filtration rate estimation * International normalized ratio (INR) or prothrombin time (PT): =\< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants * Activated partial thromboplastin time (aPTT): =\< 1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial as long as their anti-retroviral therapy does not have the potential for drug-drug interactions as judged by the treating investigator * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with history of treated central nervous system (CNS) metastases are eligible, provided they meet the following criteria: * Disease outside the CNS is present * Recovery from acute toxicity associated with the treatment to =\< Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1 or baseline (with the exception of alopecia), with no requirement for escalating doses of corticosteroids over the past 7 days * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer are allowed * Patients should be New York Heart Association Functional Classification of class 2B or better * Peripheral neuropathy grade =\< 1 * Ability to swallow and retain oral medications * Participants may not have had cytotoxic chemotherapy, immunotherapy, major surgery (other than diagnostic surgery, dental surgery or stenting), or other investigational therapy within 3 weeks prior to entering the study * Participants may not have had radiotherapy within 1 week prior to entering the study. Patients may not have had \> 25% of their bone marrow radiated. Stereotactic radiosurgery (SRS) within 1 week prior to entering the study will be allowed * Participants may not have received tyrosine kinase inhibitors (TKIs) or small molecules within 5 half-lives or 2 weeks (whichever is shorter) of study entry * Patients who have experienced adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) must have recovered, with the exception of alopecia or as otherwise specified in the eligibility criteria * The effects of the combination of ZEN003694 (ZEN-3694) and MK-3475 on the developing human fetus are unknown. For this reason and because BETi and PD-1 blocking agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after study completion. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694), MK-3475 and nab-Paclitaxel administration. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to registration. Childbearing potential is defined as: participants who have not reached a postmenopausal state (\>= 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus) * Ability to understand and the willingness to sign a written informed consent documen
Conditions Breast Cancer, Breast Reconstruction
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The outcomes of fat grafting combined with latissimus dorsi muscle flap for delayed breast reconstruction after mastectomy

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Fat grafting combined with latissimus dorsi muscle flap — Fat grafting combined with latissimus dorsi muscle flap for delayed breast reconstruction

Primary Outcomes

  • Wound infection or dehesiens (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-01
Completion: 2027-11-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sohag University
Contact Information
Study Contact:
ضياء Diaa eldeen abd elraheem Mohammed
201062263495
diaaeldeek1@gmail.com
Sohag university hospital
Interventions
  • Procedure: Fat grafting combined with latissimus dorsi muscle flap — Fat grafting combined with latissimus dorsi muscle flap for delayed breast reconstruction
Study Locations (1 sites)
Sohag university hospital, Sohag, Sohag Governorate Egypt
Eligibility Criteria
Inclusion Criteria: * female patient indicated for skin sparying mastectomy Exclusion Criteria: * female patients with stage 4 breast cancer
Conditions Breast Cancer
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine therapy (AET).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Intermittent Fasting — Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of: * An approximately fourteen-hour nightly fasting period that is followed by * An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM).

Primary Outcomes

  • Subject adherence to the intermittent fasting schedule. (Six months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-19
Completion: 2027-07-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Principal Investigators:
  • Sailaja Kamaraju, MD (PRINCIPAL_INVESTIGATOR) - Medical College of Wisconsin
Contact Information
Study Contact:
Medical College of Wisconsin Cancer Center Clinical Trials Office
866-680-0505
cccto@mcw.edu
Sailaja Kamaraju, MD
414-805-4600
skamaraju@mcw.edu
Froedtert Hospital & the Medical College of Wisconsin
Sailaja Kamaraju, MD
Froedtert Hospital & the Medical College of Wisconsin
Interventions
  • Behavioral: Intermittent Fasting — Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of: * An approximately fourteen-hour nightly fasting period that is followed by * An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM).
Study Locations (1 sites)
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: 1. Breast cancer patients ≥ 18 years old who are willing to consent to an approximately 14-hour nighttime fasting period and an approximately 10-hour daytime eating period. 2. Histologically and/or cytologically confirmed diagnosis of estrogen receptor (ER) positive (ER+) and human epidermal growth factor receptor (HER) 2 negative (HER2-) localized breast cancer (stages I-III). 1. Progesterone receptor positive or negative patients are allowed. 2. Hormone receptor positivity is defined as ER positivity in at least 1% cells by immunohistochemistry (IHC). HER 2-negative breast cancer is defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization fluorescence in situ hybridisation (FISH), chromogenic in situ hybridization (CISH), or silver-enhanced in situ hybridization (SISH) test is required. 3. Body mass index (BMI) ≥ 25. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. 5. Subject must be willing to start the intermittent fasting (IF) intervention within three months of starting adjuvant endocrine therapy (AET), or at the discretion of the treating providers, and within 30 days of study enrollment. 6. Subjects who received neoadjuvant or adjuvant chemotherapy must have recovered completely from chemotherapy-related side effects such as nausea/emesis as determined by the treating providers. 7. Subjects who received neoadjuvant endocrine therapy are eligible only after completion of their definitive surgery (i.e., when ready to start adjuvant endocrine therapy) and treating provider ensures complete closure and healing of surgical incisions. 8. Subjects who had adjuvant systemic chemotherapy within two to four weeks prior to starting the IF intervention are eligible if they have recovered from acute effects of prior therapy to near baseline as determined by the treating physician. 9. Subjects on a targeted therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitor, or selective estrogen receptor degrader (SERD), or other clinical trial participants in the adjuvant setting are eligible at the discretion of the treating physician. 10. Subject co-administered with any prescriptions that may cause dizziness, hypoglycemia, or hypotension need to be evaluated and deemed eligible by the treating physician. 11. Adequate hepatic, renal function and adequate bone marrow reserve as determined by the treating physician: 1. aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × institutional upper limit. 2. Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except for subjects with Gilbert's syndrome who may be included if their total bilirubin is ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN. 3. alkaline phosphatase (ALP) ≤ 2.5 × institutional upper limit with exception that ALP of \< 5 × ULN is acceptable in patients with elevated with ALP due to bone metastases (in the absence of liver metastases). 4. Serum creatinine \<1.5 × ULN. 5. Absolute neutrophil count (ANC) ≥1000/µL. 6. Subjects with lymphopenia are eligible at the discretion of the treating provider. i. Hemoglobin (Hb) ≥ 8g/dL. ii. Platelet count ≥ 100,000/µL. 12. Premenopausal woman: 1. Premenopausal is defined as someone who has had menses at any time in the last 12 months. For premenopausal women who are eligible for this trial, the treating physician may choose to monitor ovarian function with laboratory tests e.g., follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol as clinically indicated to assess their menopausal status. 2. Subjects must agree not to conceive throughout the study and must use accepted methods of contraception. 3. Women of childbearing potential must have a negative pregnancy test within seven days of registration and or seven to 10 days prior to starting study treatment. 13. Subjects who have an atypical sleep-wake schedule or different eating schedules are eligible at the discretion of the study investigators and dietitians as long as they agree to nightly fasting. 14. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Subject who works late night shifts. 2. Subject that was or currently on a fasting diet (e.g., Keto diets), intervention, or an agent (e.g., Ozempic) for the explicit purpose of inducing weight loss in the past one year. 3. Subject with a history of an eating disorder (e.g., anorexia nervosa, bulimia nervosa). 4. Presence of diabetes. 5. Presence of chronic dizziness or vertigo. 6. Presence of endocrine disorders prone to fluctuations in blood sugar (e.g., multiple neuroendocrine disorders, adrenal disorders, chronic hypoglycemia). 7. Poorly controlled neurological disorders as determined by the treating physician (e.g., epilepsy, Parkinson's disease, myasthenia gravis, syncope, pre-syncopal episodes). 8. Poorly controlled co-existing cardiac disease as determined by the treating physician, such as chronic hypotension, symptomatic congestive heart failure (New York Heart Association III-IV), unstable angina, arrythmia (e.g., atrial fibrillation, bradycardia, tachycardia). 9. History of heavy alcohol use as determined by the treating physician. 10. History of liver disease (cirrhosis, active hepatitis) or chronic renal disease. 11. Untreated or active infections such as hepatitis, human immunodeficiency virus (HIV), chronic unhealed infections. 12. Clinically significant illness or systemic disease as determined by the treating physician. 13. Recent hospitalization for a major illness, as determined by the treating physicians, within one month of enrollment. 14. Subject who is pregnant or breastfeeding. Subjects who become pregnant while on the study will be excluded.
Conditions Breast Cancer
Phase EARLY_PHASE1
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to study the safety, feasibility, histologic and immunological effects of Mitazalimab, a CD40 agonistic antibody, when administered either alone or in combination with PD-1 inhibition prior to surgical resection. The investigator hypothesizes that preoperative administration of CD40 agonist with or without PD-1 inhibitor intratumorally will demonstrate an acceptable safety profile, will not result in an unplanned delay in surgery, and will lead to increased immune activation. Subjects will receive a single intratumoral dose of CD40 agonist with or without PD-1 inhibitor 7 or more days prior to surgery and will be followed for safety, feasibility, immune, and pathologic responses.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Intratumoral Mitazalimab — Intratumoral agonistic CD40
  • Drug: Intratumoral Nivolumab — Checkpoint inhibitor

Primary Outcomes

  • Occurrence of Grade 3 or higher adverse events as assessed by CTCAE v5.0 (Within 30 days of treatment)
  • Feasibility of CD40 agonist (Mitazalimab) with/without PD-1 inhibitor (Nivolumab) prior to surgery (14 days after planned surgical date)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-04-27
Completion: 2033-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jennifer Zhang
Collaborators: Alligator Bioscience AB
Principal Investigators:
  • Jennifer Zhang, MD (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Jennifer Zhang, MD
215-573-9348
jennifer.zhang@pennmedicine.upenn.edu
Julia Lewandowski
215-573-9348
julia.lewandowski@pennmedicine.upenn.edu
Jennifer Zhang, MD
215-573-9348
jennifer.zhang@pennmedicine.upenn.edu
Hospital of the University of Pennsylvania
Interventions
  • Drug: Intratumoral Mitazalimab — Intratumoral agonistic CD40
  • Drug: Intratumoral Nivolumab — Checkpoint inhibitor
Study Locations (1 sites)
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: 1. Signed and dated written IRB-approved informed consent. 2. Age ≥18 years. 3. Body weight \> 40kg 4. Stage I-III or recurrent resectable breast cancer to be treated with curative-intent 5. Planning to undergo upfront surgery as part of routine clinical care 6. Discussion with the treating or study medical oncologist re: the potential of sending an Oncotype evaluation (if ER+HER2-) on the core needle biopsy sample 7. Availability of the core needle biopsy sample for correlative studies 8. Surgery to be performed at a University of Pennsylvania Hospital 9. Life expectancy of at least 12 weeks. 10. Adequate bone marrow, hepatic, and renal function. ANC (Absolute Neutrophil Count) ≥ 1.5x109 cell/ml, platelets ≥75,000 /mm3, hemoglobin ≥9.0 g/dL, total serum bilirubin within 1.5 x upper limit of normal (ULN) unless Gilbert's, AST/ALT, within 2.5 x ULN, Albumin ≥3g/dL, and all tests performed within 4 weeks prior to administration of Study Treatment. 11. ECG with no clinically significant findings as assessed by the investigator. 12. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1. 13. Female patients of childbearing potential who are not abstinent and intend to be sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from the time of screening throughout the total duration of the drug treatment and the drug washout period (90 days after therapy). Non-sterilized male partners of a female patient of childbearing potential must use male condom plus spermicide throughout this period. Female patients should also refrain from breastfeeding throughout this period. 14. Able and willing to comply with all study procedures. Exclusion Criteria: 1. Metastatic disease. 2. Planned neoadjuvant therapy, i.e., not undergoing upfront surgery. 3. Known history of hepatitis B or C with active viral replication. 4. Administration of any live vaccine within 28 days of first dose of study treatment. 5. Prior CD40 or anti-PD-1 agonist therapy. 6. Participation in another interventional clinical trial within 30 days before receiving first dose of study treatment. However, the subject may participate in observational studies. 7. Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint. 8. Current or prior use of immunosuppressive medication within 14 days before study treatment. The following are exceptions to this criterion: 1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) 2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent 9. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. 10. History of allogenic organ transplantation 11. Active or prior documented autoimmune disease. Examples include inflammatory bowel disease \[e.g., colitis or Crohn's disease\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis\], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\]. The following are exceptions to this criterion: 1. Patients with vitiligo or alopecia 2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or type 1 DM controlled with insulin 3. Any chronic skin condition that does not require systemic therapy 4. Patients without active autoimmune disease in the last 5 years may be included but only after consultation with the study physician 5. Patients with celiac disease controlled by diet alone 12. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent 13. History of another active malignancy except for non-melanoma skin cancer, lentigo maligna or other carcinoma in situ 14. History of active primary immunodeficiency 15. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. 16. Body weight \> 110 kg. 17. Actively breastfeeding. -
Conditions Breast Cancer, Lung Cancer, Muscle Invas...
Phase Not Applicable
Enrollment 9600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Primary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development (8 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-21
Completion: 2035-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 9600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Natera, Inc.
Contact Information
Study Contact:
SCORE Study team
650-489-9050
contactscorestudy@natera.com
Jamie McKenzie, MD
650-489-9050
contactscorestudy@natera.com
Natera, Inc.
Interventions
N/A
Study Locations (1 sites)
Natera, Inc., Austin, Texas 78753 United States
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age or older. 2. Any patient that has an untreated primary solid malignancy within the following cohorts: 1. Breast cancer 2. Lung cancer 3. Muscle invasive bladder cancer 4. Rectal cancer 5. Pancreatic cancer 6. Ovarian cancer 7. Gastroesophageal cancer 8. Prostate cancer 9. Melanoma 10. Hepatic/liver cancer 11. Uterine/endometrial cancer 12. Head and neck Cancer 3. The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging. 4. Eastern Cooperative Oncology Group performance status ≤ 2. 5. Able to tolerate venipuncture for research blood draw(s). 6. Consent to provide residual tumor tissue for research. 7. Willing and able to comply with the study requirements. 8. Signed informed consent(s) must be obtained prior to participation in the study. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers. 3. Has initiated postoperative systemic treatment. 4. At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection. 5. History of bone marrow or organ transplant. 6. Serious medical conditions that may adversely affect ability to participate in the study.
Conditions HER2-positive Early-stage Breast Cancer
Phase PHASE2
Enrollment 50
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biomarker assay, HER2 Activation Response Predictive Signature (HARPS) to identify HARPS-positive breast cancers. To assess 3-year invasive disease-free survival (iDFS) in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer. To correlate changes in ctDNA with treatment outcomes in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer. To understand the changes in quality of life (QOL) measure in patients with HARPS-positive HER2-positive breast cancer treated using an adaptive neoadjuvant trial design.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab — Trastuzumab is a targeted antibody therapy used to treat HER2-positive breast and stomach cancers by blocking the growth-stimulating HER2 protein
  • Drug: Pertuzumab — targeted therapy, a monoclonal antibody, used with other drugs (like trastuzumab and chemotherapy) to treat HER2-positive breast cancer, blocking HER2 proteins on cancer cells to stop their growth, and used for metastatic, locally advanced, or early-stage high-risk cases before or after surgery
  • Drug: Docetaxel — will be used with HARPS Negative: intravenous chemotherapy medication used to treat breast, lung, prostate, gastric, and head/neck cancers
  • Drug: Carboplatin — will be used with HARPS Negative: a platinum-based chemotherapy drug used primarily to treat advanced ovarian cancer, often in combination with other agents, as well as lung, head and neck, and brain cancers

Primary Outcomes

  • Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) Assessed by CTCAE v5.0 (up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-26
Completion: 2028-06-30
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rutgers, The State University of New Jersey
Contact Information
Study Contact:
Mridula A George
732-235-9692
mridula@cinj.rutgers.edu
Mridula George, MD
7322359692
mridula@.rutgers.edu
RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center
Mridula George, MD
7322359692
mridula@.rutgers.edu
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Interventions
  • Drug: Trastuzumab — Trastuzumab is a targeted antibody therapy used to treat HER2-positive breast and stomach cancers by blocking the growth-stimulating HER2 protein
  • Drug: Pertuzumab — targeted therapy, a monoclonal antibody, used with other drugs (like trastuzumab and chemotherapy) to treat HER2-positive breast cancer, blocking HER2 proteins on cancer cells to stop their growth, and used for metastatic, locally advanced, or early-stage high-risk cases before or after surgery
  • Drug: Docetaxel — will be used with HARPS Negative: intravenous chemotherapy medication used to treat breast, lung, prostate, gastric, and head/neck cancers
  • Drug: Carboplatin — will be used with HARPS Negative: a platinum-based chemotherapy drug used primarily to treat advanced ovarian cancer, often in combination with other agents, as well as lung, head and neck, and brain cancers
Study Locations (7 sites)
RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey 07202 United States
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey 08690 United States
RWJBarnabas Health - Monmouth Medical Center, Long Branch, New Jersey 07740 United States
Rutgers Cancer Institute, New Brunswick, New Jersey 08901 United States
RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey 07112 United States
RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerville, New Jersey 08876 United States
RWJBarnabas Health - Community Medical Center, Toms River, New Jersey 08755 United States
Eligibility Criteria
Inclusion Criteria: * Inclusion Criteria 1. Tumor size greater than 2cm or lymph node positive by imaging or clinical exam (cT2-T3 N0-2) 2. Tumors must be HER2 positive either by IHC (3+) or by IHC 2+ and FISH positive. 3. Patient must have known estrogen receptor (ER) and progesterone receptor (PR) status locally determined prior to study entry 4. Patient must have adequate tumor for HARPS testing. 5. Patients must have ctDNA collection prior to treatment on trial. 6. Patient must be able to do breast MRI as determined by the study 7. Baseline LVEF \> 50% (Most recent within the last 5 years) 8. No prior history of systemic treatment with anthracyclines-based chemotherapy. 9. Adequate bone marrow function: * ANC ≥ 1500/uL * platelet count ≥ 100,000/uL * hemoglobin ≥ 9.0 g/dL 10. Adequate hepatic function: * Total bilirubin ≤ 1.5 X ULN * AST (SGOT) ≤ 5 X ULN * ALT (SGPT) ≤ 5 X ULN 11. Patients with biliary obstruction must have restored biliary flow by placement of an endoscopic common bile duct stent or a percutaneous drainage. 12. Adequate renal function, Creatinine \< 1.5x institutional ULN or calculated creatinine clearance ≥ 50 mL/min as estimated using the Cockcroft-Gault formula. 13. Ability to understand the nature of this study protocol and give written informed consent. 14. Willingness and ability to comply with scheduled visits and treatment plans 15. Prior cancers allowed if no evidence of disease in last 5 years. Prior history of ipsilateral invasive breast cancers are not allowed. Exclusion Criteria: 1. Previous treatment with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy for invasive breast cancer. Exception: patients can start upto 1 cycle of HP prior to starting treatment on study. 2. cT4 and/or cN3 tumors 3. Evidence of metastatic disease by routine clinical assessment 4. Bilateral breast cancer 5. History of other malignancy within the last five years prior to first dose of study drug administration, except for curatively treated basal and squamous cell carcinoma of the skin and/or in situ cervical carcinoma 6. Left ventricular ejection fraction (LVEF) below 50% as determined by multiple-gated acquisition (MUGA) scan or echocardiography (ECHO) 7. No active liver disease. 8. Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study. 9. Pre-existing sensory neuropathy \> grade 1. 10. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months. 11. Serious non-healing wound, ulcer, or bone fracture 12. Patient with uncontrolled and/ or active infection with HIV, Hepatitis B or Hepatitis C. 13. Patient who has a history of allergy or hypersensitivity to any of the study drugs. 14. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
Conditions Breast Cancer
Phase Not Applicable
Enrollment 560
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Patients who were diagnosed with breast cancer and have finished their treatment will be given the opportunity to be part of this study. These patients will have been attending surveillance at the Breast Centre in Beaumont Hospital, Ireland for 2 years prior. These patients, who are doing well after breast cancer treatment, will be given the opportunity to enrol in this study, potentially being discharged from in person surveillance after 2 years, while still attending for their annual mammogram. Investigators intend to find out if a simpler follow-up plan could work just as safely, while also improving the patients quality of life.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Deescalation of surveillance — Patients will attend hospital-based in-person specialist surveillance clinics according to the current practice post initial diagnosis for the first two years following curative resection and treatment of their primary breast cancer and then discharged from the service (i.e.: patients will receive six monthly specialist follow-up appointments for the first 24 months). Mammographic surveillance will be as described for the control group. Every patient will undergo an annual mammogram until the age of seventy years (or if aged 70 at the time of diagnosis, they will have an annual mammogram for five years in total). As per standard practice all results from these annual mammogram studies will be copied to the patients' general practitioner. If any abnormalities are detected on mammogram the patient will be contacted. All participants will complete the health-related quality of life questionnaire, EQ5D5L at the 24 (2 year), 36 (3 year), 48 (4 year) and 50 month (5 year) timepoint.

Primary Outcomes

  • Health Related Quality of Life (Participants will complete the questionnaire (paper-based or via telephone with the Advanced Nurse Practitioner) at 2, 3, 4, and 5 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-11
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 560 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal College of Surgeons, Ireland
Contact Information
Study Contact:
Emma Forde, Medical Doctor & Scientist
+353896126509
eforde@rcsi.com
Emma E Forde, Licensed doctor
+353 018092060
eforde@rcsi.ie
Beaumont Hospital
Professor ADK Hill, Professor and Chairman of Surgery
+353 018092060
ADKHILL@rcsi.ie
Beaumont Hospital
Interventions
  • Other: Deescalation of surveillance — Patients will attend hospital-based in-person specialist surveillance clinics according to the current practice post initial diagnosis for the first two years following curative resection and treatment of their primary breast cancer and then discharged from the service (i.e.: patients will receive six monthly specialist follow-up appointments for the first 24 months). Mammographic surveillance will be as described for the control group. Every patient will undergo an annual mammogram until the age of seventy years (or if aged 70 at the time of diagnosis, they will have an annual mammogram for five years in total). As per standard practice all results from these annual mammogram studies will be copied to the patients' general practitioner. If any abnormalities are detected on mammogram the patient will be contacted. All participants will complete the health-related quality of life questionnaire, EQ5D5L at the 24 (2 year), 36 (3 year), 48 (4 year) and 50 month (5 year) timepoint.
Study Locations (1 sites)
Beaumont Hospital, Dublin, D09Y177 Ireland
Eligibility Criteria
Inclusion Criteria: * Female participants aged 18 years or older * Prior diagnosis of primary breast cancer treated with curative intent * Currently under cancer surveillance and at the 24-month follow-up timepoint * No clinical or radiological evidence of disease recurrence or metastasis at the time of recruitment (e.g., no palpable mass, skin or nipple changes, or suspicious findings on imaging) * Able to read, write, and speak English sufficiently to complete the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire (paper-based or via telephone) * Resident in the Republic of Ireland with a fixed address and intention to continue follow-up within the Irish healthcare system Exclusion Criteria: * Evidence of breast cancer recurrence or metastatic disease at the time of recruitment * Inability to provide informed consent * Inability to complete study questionnaires (e.g., due to language barriers or cognitive impairment) * Not resident in the Republic of Ireland or not intending to remain in follow-up within the Irish healthcare system
Conditions Breast Cancer
Phase Not Applicable
Enrollment 234
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of the retrospective phase of this study is to validate the specificity and the sensitivity of two Real-Time quantitative PCR based techniques in order to support the gold-standard approaches used to evaluate the HER2 gene status in breast cancer. Furthemore, HER2-low patients are enrolled in a prospective phase, both in early stage and in case of recurrence, in order to monitorate HER2 expression levels changes under treatments by using liquid biopsy. The first aim is to be able to distinguish responders vs non-responders earlier than the standard monitoring through tumoral markers and medical examination.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Breast cancer patients undergone surgical and systemic therapy (At baseline)
  • Early-stage HER2-low breast cancer patients undergoing surgical and systemic therapy (At baseline)
  • Metastatic HER2-low patients in treatment with Trastuzumab-Deruxtecan (Every 4 months from the start of therapy,assessed up to 60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-08
Completion: 2028-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 234 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Principal Investigators:
  • Sara Coluccelli, PhD (PRINCIPAL_INVESTIGATOR) - IRCCS Azienda Ospedaliero-Universitaria di Bologna
Contact Information
Study Contact:
Sara Coluccelli, PhD
+393290928473
sara.coluccelli@aosp.bo.it
Sara Coluccelli, PhD
+393290928473
sara.coluccelli@aosp.bo.it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Interventions
N/A
Study Locations (1 sites)
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Bologna 40138 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Histologic confirmation of breast cancer from 1/1/2022 * Patient treated with systemic and surgical therapy (retrospective phase) * Signed informed consent * HER2-0 and/or HER2-low patient, according to IHC and D-DISH/FISH, treatable with systemic and surgical therapy (prospective phase) Exclusion Criteria: * Lack of molecular classification on the basis of prognostic-predictive markers ER, PR, Ki67 and HER2 (Luminal A, Luminal B HER2-positive, Luminal B HER2- negative, HER2-positive, Triple negative) * Prior neoplasms, other than the neoplasm under investigation, arised within the past 5 years * Missing histological diagnosis of HER2-0 and/or HER2-low breast cancer (prospective phase)